Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7445-7456

  VanBrocklin, Henry F ^a   Lim, John K ^a,b,d   Coffing, Stephanie L ^c,f   Hom, Darren L ^a   Negash, Kitaw ^a,e   Ono, Michele Y ^a   Gilmore, Jennifer L ^c   Bryant, Ianthe ^c   Riese II, David J ^c  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Hitachi High Technologies America   (United States)

^e PFIZER INC   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2' FLUOROANILINO) 6,7 DIETHOXYQUINAZOLINE; 4 (3' BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3' CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; OCTANOL; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DIMERIZATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING SYSTEM; ISOTOPE LABELING; LABELING INDEX; MEDIATOR RELEASE; PARTITION COEFFICIENT; RADIOMETRY; RECEPTOR AFFINITY; SCREENING; STRUCTURE ANALYSIS; SYNTHESIS;

ANILINE COMPOUNDS; ANIMALS; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CELL LINE; DNA; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; LIGANDS; MICE; NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 28544439285     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050607w     Document Type: Article

References (59)

1. Hanks, S. K.; Quinn, A. M.; Hunter, T. The protein tyrosine kinase family: Conserved features and phylogeny of the catalytic domains. Science 1988, 241, 42-52.
2. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
3. Yarden, Y.; Ullrich, A. Growth Factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988, 57, 443-478.
4. Downward, J.; Yarden, Y.; Mayes, E.; Scrace, G.; Totty, N. et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307, 521-527.
5. Ullrich, A.; Coussens, L.; Hayflick, J. S.; Dull, T. J.; Gray, A. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
6. Yarden, Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and the therapeutic opportunities. Eu. J. Cancer 2001, 37, S3-S8.
7. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137.
8. Gasparini, G.; Bevilacqua, P.; Pozza, F.; Meli, S.; Boracchi, P. et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer 1992, 66, 970-976.
9. Toi, M.; Nakamura, T.; Mukaida, H.; Wada, T.; Osaki, A. et al. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 1990, 65, 1980-1984.
10. Klijn, J.; Berns, P.; Schmitz, P.; Foekens, J. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr. Rev. 1992, 13, 3-17.
11. Koenders, P.; Beex, L.; Geurts-Moespot, A.; Heuvel, J.; Kienhuis, C. et al. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991, 51, 4544-4548.
12. Mori, T.; Morimoto, T.; Komaki, K.; Monden, Y. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 1991, 68, 532-537.
13. Bridges, A. J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr. Med. Chem. 1999, 6, 825-843.
14. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 1999, 82, 231-239.
15. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1, 117-123.
16. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharm. Ther. 1999, 82, 195-206.
17. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharm. Ther. 1999, 82, 241-250.
18. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550-6565.
19. Carpenter, G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 1987, 56, 881-914.
20. Andersson, A.; Capala, J.; Carlsson, J. Effects of EGF-dextrantyrosine- 1311 conjugates on the clonogenic survival of cultured glioma cells. J. Neurooncol. 1992, 14, 213-223.
21. Schatten, C.; Patiesky, N.; Vavra, N.; Ehrenbock, P.; Angelberger, P. et al. Lymphoscintigraphy with 123I-labeled epidermal growth factor. Lancet 1991, 337, 395-396.
22. Orlova, A.; Bruskin, A.; Sjostrom, A.; Lundqvist, H.; Gedda, L. et al. Cellular Processing of 125I- and 111In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl. Med. Biol. 2000, 27, 827-835.
23. Capala, J.; Barth, R. F.; Bailey, M. Q.; Fenstermaker, R. A.; Marek, M. J. et al. Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjugat Chem. 1997, 8, 289-295.
24. Rusckowski, M.; Qu, T.; Chang, F.; Hnatowich, D. J. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J. Pept. Res. 1997, 50, 393-401.
25. Yang, W.; Earth, R. F.; Leveille, R.; Adams, D. M.; Ciesielski, M. et al. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent. J. Neurooncol. 2001, 55, 19-28.
26. Reilly, R. M.; Kiarash, R.; Cameron, R. G.; Porlier, N.; Sandhu, J. et al. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J. Nucl. Med. 2000, 41, 429-438.
27. 111In labeled human epidermal growth factor derivitized with a bifunctional metal-chelating peptide. Bioconjugate Chem. 1995, 6, 683-690.
28. Reilly, R. M.; Kiarash, R.; Sandhu, J.; Lee, Y. W.; Cameron, R. G. et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J. Nucl. Med. 2000, 41, 903-911.
29. Cammilleri, S.; Kaphan, G.; Berthois, Y.; Sues, S.; Khelifa, F. et al. Biodistribution and imaging studies with radioactively labeled monoclonal antibody anti-epidermal growth factor receptor in athymic mice bearing human mammary tumor. Antibody Immunoconjugates Radiopharm. 1991, 4, 501-506.
30. Kalofonos, H.; Pawlikowska, T.; Hemingway, A.; Courtenay-Luck, N.; Dhokia, B. et al. Antibody guided diagnoisis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J. Nucl. Med. 1989, 20, 1636-1645.
31. Divgi, C. R.; Welt, S.; Kris, M.; Real, F. X.; Yeh, S. D. et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma [see comments]. J. Natl. Cancer Inst. 1991, 83, 97-104.
32. Ramos-Suzarte, M.; Rodriguez, N.; Oliva, J. P.; Iznaga-Escobar, N.; Perera, A. et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J. Nucl. Med. 1999, 40, 768-775.
33. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A. et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
34. Fry, D.; Kraker, A.; McMichael, A.; Ambroso, L.; Nelson, J. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
35. Rewcastle, G.; Denny, W.; Bridges, A.; Zhou, H.; Cody, D. et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)-quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
36. 125I]iodoanilino-6,7-dialkoxyquinazolines: Ra-diolabeled epidermal growth factor tyrosine kinase inhibitors. J. Labelled Compd. Radiopharm. 2000, 43, 1183-1191.
37. Mulholland, G. K.; Winkle, W.; Moch, B. H.; Sledge, G. Radioiodinated Epidermal Growth Factor Receptor Ligands as tumor probe. Dramatic potentiation of binding to MDA-486 cancer cells in the presence of EGF. J. Nucl. Med. 1995, 36, 71P.
38. Bonasera, T. A.; Ortu, G.; Rozen, Y.; Krais, R.; Freedman, N. M. et al. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl. Med. Biol. 2001, 28, 359-374.
39. Snyder, S. E.; Sherman, P. S.; Blair, J. B. 4-(3-chloro-4-[18F]- fluorophenylamino)-6,7-dimethoxyquinazoline: A radiolabeled EGF receptor inhibitor for imaging tumor biochemistry with PET. J. Nucl. Med. 2000. 41 Suppl, 233p.
40. Mulholland, G. K.; Zheng, Q.-H.; Winkle, W. L.; Carlson, K. A. Synthesis and Biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands. J. Nucl. Med. 1997, 38, 141P.
41. Johnstrom, P.; Frediksson, A.; Thorell, J.-O.; Stone-Elander, S. Synthesis of [Methoxy-11C]PD153035, a selective EGF receptor Tyrosine Kinase Inhibitor. J. Labelled Compd. Radiopharm. 1998, 41, 623-629.
42. Frediksson, A.; Johnstrom, P.; Thorell, J.-O.; von Heijne, G.; Hassan, M. et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci. 1999, 65, 165-174.
43. Johnstrom, P.; Frediksson, A.; Thoreil, J.-O.; Hassan, M.; Kogner, P. et al. Synthesis and in vivo biodistribution of tyrosine kinase inhibitor, [Methoxy-1 IC]PD 153035. J. Labelled Compd. Radiopharm. 1997, 40, 377-379.
44. Minick, D.; Frenz, J.; Patrick, M.; Brent, D. A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography. J. Med. Chem. 1988, 31, 1923-1933.
45. Pomper, M.; VanBrocklin, H.; Thieme, A.; Thomas, R.; Kiesewetter, D. et al. 11β-methoxy-, 11β-ethyl- and 17α-ethynyl-substi-tuted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. J. Med. Chem. 1990, 33, 3143-3155.
46. Eckelman, W. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. Nucl. Med. Biol. 1994, 21, 759-769.
47. Eckelman, W. C. Sensitivity of New Radiopharmaceuticals. Nucl. Med. Biol. 1998, 25, 169-173.
48. Kuhnast, B.; Dolle, F.; Vaufrey, F.; Hinnen, F.; Crouzel, C. et al. Fluorine-18 labeling of oligonucleotides bearing chemically modified ribose-phosphate backbones. J. Labelled Compd. Radiopharm. 2000, V43, 837-848.
49. Mishani, E.; Cristel, M. E.; Dence, C. S.; McCarthy, T. J.; Welch, M. J. Application of a novel phenylpiperazine formation reaction to the radiosynthesis of a model fluorine-18-labeled radiopharmaceutical (18FTFMPP). Nucl. Med. Biol. 1997, 24, 269-273.
50. Mu, F.; Coffing, S. L.; Riese, D. J. I.; Geahlen, R. L.; Verdier-Pinard, P. et al. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. J. Med. Chem. 2001, 44, 441-452.
51. Plowman, G. D.; Green, J. M.; Culouscou, J. M.; Carlton, G. W.; Rothwell, V. M. et al. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993, 366, 473-475.
52. Riese, D. J. I.; Komurasaki, T.; Plowman, G. D.; Stern, D. F. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem. 1998, 273, 11288-11294.
53. Riese, D. J., 2nd; van Raaij, T. M.; Plowman, G. D.; Andrews, G. C.; Stern, D. F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. [Erratum: Mol. Cell. Biol. 1996 16 (2), 735]. Mol. Cell. Biol. 1995, 15, 5770-5776.
54. Hwang, E. S.; Riese, D. J. I.; Settleman, J.; Nilson, L. A.; Honig, J. et al. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J. Virol. 1993, 67, 3720-3729.
55. Gazit, A.; Osherov, N.; Gilon, C.; Levitzki, A. Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: Potent inhibitors of EGF receptor tyrosine kinase in vitro. J. Med. Chem. 1996. 39, 4905-4911.
56. Dischino, D. D.; Welch, M. J.; Kilbourn, M. R.; Raichle, M. E. Relationship between lipophilicity and brain extraction of C-11 labeled radiopharmaceuticals. J. Nucl. Med. 1983, 24, 1030-1038.
57. Katzenellenbogen, J. A.; Heiman, D. F.; Carlson, K. E.; Lloyd, J. E. In vivo and in vitro steroid receptor assays in the design of estrogen radiopharmaceuticals. In Receptor-Binding Radiotracers; CRC Press: Boca Raton, FL, 1982; Volume I, Chapter 6; pp 93-126.
58. Srinivasan, R., Poulsom, R., Hurst, H. C. and Gullick, W. J. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 1998, 185, 236-245.
59. Bacus, S. S., Chin, D., Yarden, Y., Zelnick, C. R. and Stern, D. F. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am. J. Pathol. 1996, 148, 549-558.